All Stories

Otsuka's Taiho pays $400M for Swiss partner to 'turbocharge' 3 ADCs to clinic

Otsuka’s Taiho Pharmaceutical is paying $400 million upfront to acquire Switzerland’s Araris Biotech and its antibody-drug conjugate linker platform.

Mar 17, 2025 - 13:18
 0
Otsuka's Taiho pays $400M for Swiss partner to 'turbocharge' 3 ADCs to clinic
Otsuka’s Taiho Pharmaceutical is paying $400 million upfront to acquire Switzerland’s Araris Biotech and its antibody-drug conjugate linker platform.
Read More

Tags:

Previous Article

Citygate diversifies with launch of new leasing business

Next Article

Q Energy to build 200MW solar PV in Spain

Related Posts

US judge blocks Trump administration from cutting NIH grants amid ongoing litigation

US judge blocks Trump administration from cutting NIH g...

Mar 5, 2025  0

CF-focused Sionna goes public in $135M IPO, while Aardvark plots $103M listing

CF-focused Sionna goes public in $135M IPO, while Aardv...

Feb 9, 2025  0

Corbus posts first US data on challenger to Pfizer’s ADC Padcev

Corbus posts first US data on challenger to Pfizer’s AD...

Feb 14, 2025  0